Cambridge Investment Research Advisors
UTHR icon

Cambridge Investment Research Advisors’s United Therapeutics UTHR Stock Holding History

Cambridge Investment Research Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.05M Buy
5,625
+50
+0.9% +$28.2K 0.01% 1370
2026
Q1 		$3.31M Buy
5,575
+1,782
+47% +$887K 0.01% 1222
2025
Q4 		$1.85M Buy
3,793
+1,811
+91% +$843K ﹤0.01% 1603
2025
Q3 		$831K Buy
1,982
+91
+5% +$30.6K ﹤0.01% 2196
2025
Q2 		$543K Sell
1,891
-7,288
-79% -$2.18M ﹤0.01% 2462
2025
Q1 		$2.83M Buy
9,179
+2,211
+32% +$758K 0.01% 1136
2024
Q4 		$2.46M Sell
6,968
-4,208
-38% -$1.55M 0.01% 1213
2024
Q3 		$4M Buy
11,176
+8,589
+332% +$2.9M 0.01% 933
2024
Q2 		$824K Buy
2,587
+907
+54% +$240K ﹤0.01% 1909
2024
Q1 		$386K Sell
1,680
-11
-0.7% -$2.48K ﹤0.01% 2499
2023
Q4 		$372K Sell
1,691
-14
-0.8% -$3.23K ﹤0.01% 2437
2023
Q3 		$385K Buy
1,705
+141
+9% +$32.5K ﹤0.01% 2298
2023
Q2 		$345K Sell
1,564
-4,539
-74% -$1.01M ﹤0.01% 2423
2023
Q1 		$1.37M Buy
6,103
+4,291
+237% +$1.06M 0.01% 1364
2022
Q4 		$504K Buy
1,812
+37
+2% +$9.34K ﹤0.01% 2007
2022
Q3 		$372K Buy
1,775
+298
+20% +$66.6K ﹤0.01% 2188
2022
Q2 		$348K Buy
+1,477
New +$300K ﹤0.01% 2247

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Cambridge Investment Research Advisors's UTHR Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its United Therapeutics (UTHR) stake by 0.9% in Q2 2026, buying an estimated $28.2K and bringing the position to 5,625 shares worth $3.05M. The position accounts for 0.01% of the portfolio, ranked #1370.

Cambridge Investment Research Advisors first reported a position in UTHR in Q2 2022 and has held it in 17 quarters since. The position peaked at $4M in Q3 2024. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Cambridge Investment Research Advisors held 5,625 shares of United Therapeutics worth $3.05M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 50 United Therapeutics shares in Q2 2026, an estimated $28.2K.
  • United Therapeutics made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1370 holding.
  • Cambridge Investment Research Advisors first reported a position in United Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • Cambridge Investment Research Advisors's United Therapeutics position peaked at $4M in Q3 2024.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.